LASP1 and chronic myelogenous leukemia, BCR-ABL1 positive: Knockout of LASP1, as a model for the observed reduced LASP1 levels in non‐responders and blast crisis patients, enhances proliferation under TKI treatment, impairs migration and favours survival of CML cells.